The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Somatoform Disorders

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Somatoform Disorders


Psychiatry related information on Somatoform Disorders


High impact information on Somatoform Disorders


Chemical compound and disease context of Somatoform Disorders


Anatomical context of Somatoform Disorders


Gene context of Somatoform Disorders

  • RESULTS: Diagnostic criteria for somatoform pain disorder were fullfilled in 73.3% of the ICPP patients, 60% of the ACPP patients and none of the controls [19].
  • Panic, generalized anxiety, obsessive-compulsive and somatoform disorders were equally distributed across MDD onset groups [20].
  • Other investigators have found evidence of increased prevalence of depression, anxiety, and somatization disorders in MCS patients and have concluded that their psychiatric conditions account for the clinical picture [21].
  • Across ECA sites a screening threshold of five of 11 symptoms correctly identified 41 of 42 respondents with DIS/DSM-III somatization disorder (97.6%) while correctly classifying 14,600 of 14,750 (99.0%) without the disorder [22].
  • The objective of this study was to validate the Spanish version of the Othmer and DeSouza Screening Test for Somatization Disorder [23].

Analytical, diagnostic and therapeutic context of Somatoform Disorders


  1. The voltage-gated calcium channel UNC-2 is involved in stress-mediated regulation of tryptophan hydroxylase. Estevez, M., Estevez, A.O., Cowie, R.H., Gardner, K.L. J. Neurochem. (2004) [Pubmed]
  2. Complaints of constipation in obsessive-compulsive disorder. North, C.S., Napier, M., Alpers, D.H., Spitznagel, E.L. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. (1995) [Pubmed]
  3. Depressive disorders in primary care: prevalence, functional disability, and identification. Williams, J.W., Kerber, C.A., Mulrow, C.D., Medina, A., Aguilar, C. Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine. (1995) [Pubmed]
  4. Illness behavior and psychosocial factors in diffuse upper limb pain disorder: a case-control study. White, P.D., Henderson, M., Pearson, R.M., Coldrick, A.R., White, A.G., Kidd, B.L. J. Rheumatol. (2003) [Pubmed]
  5. Self-rated general health and psychiatric disorders in a general population sample. John, U., Meyer, C., Rumpf, H.J., Schumann, A., Dilling, H., Hapke, U. Eur. Psychiatry (2005) [Pubmed]
  6. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database. Saletu, B., Prause, W., Anderer, P., Mandl, M., Aigner, M., Mikova, O., Saletu-Zyhlarz, G.M. Neuropsychobiology (2005) [Pubmed]
  7. Alexithymia in somatoform and depressive disorders. Duddu, V., Isaac, M.K., Chaturvedi, S.K. Journal of psychosomatic research. (2003) [Pubmed]
  8. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Phillips, K.A., Albertini, R.S., Rasmussen, S.A. Arch. Gen. Psychiatry (2002) [Pubmed]
  9. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Hollander, E., Allen, A., Kwon, J., Aronowitz, B., Schmeidler, J., Wong, C., Simeon, D. Arch. Gen. Psychiatry (1999) [Pubmed]
  10. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Phillips, K.A. The American journal of psychiatry. (2005) [Pubmed]
  11. Male body image in Taiwan versus the West: Yanggang Zhiqi meets the Adonis complex. Yang, C.F., Gray, P., Pope, H.G. The American journal of psychiatry. (2005) [Pubmed]
  12. Obsessive-compulsive disorder in relation to body dysmorphic disorder. Tanquary, J., Lynch, M., Masand, P. The American journal of psychiatry. (1992) [Pubmed]
  13. Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Barr, L.C., Goodman, W.K., Price, L.H. The American journal of psychiatry. (1992) [Pubmed]
  14. A case report of successful treatment of dysmorphophobia with tranylcypromine. Jenike, M.A. The American journal of psychiatry. (1984) [Pubmed]
  15. Elevation of immunoreactive CSF TRH in depressed patients. Banki, C.M., Bissette, G., Arato, M., Nemeroff, C.B. The American journal of psychiatry. (1988) [Pubmed]
  16. Biochemical measures in patients with a somatoform pain disorder, before, during, and after treatment with amitriptyline with or without flupentixol. Van Kempen, G.M., Zitman, F.G., Linssen, A.C., Edelbroek, P.M. Biol. Psychiatry (1992) [Pubmed]
  17. Elevated plasma vasopressin and normal cerebrospinal fluid angiotensin-converting enzyme in chronic pain disorder. Wahlbeck, K., Sundblom, M., Kalso, E., Tigerstedt, I., Rimón, R. Biol. Psychiatry (1996) [Pubmed]
  18. A segmental chronic pain syndrome in rats associated with intrathecal infusion of NMDA: evidence for selective action in the dorsal horn. Zochodne, D.W., Murray, M., Nag, S., Riopelle, R.J. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. (1994) [Pubmed]
  19. Chronic pelvic pain as a somatoform disorder. Ehlert, U., Heim, C., Hellhammer, D.H. Psychotherapy and psychosomatics. (1999) [Pubmed]
  20. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Alpert, J.E., Fava, M., Uebelacker, L.A., Nierenberg, A.A., Pava, J.A., Worthington, J.J., Rosenbaum, J.F. Biol. Psychiatry (1999) [Pubmed]
  21. An olfactory-limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders. Bell, I.R., Miller, C.S., Schwartz, G.E. Biol. Psychiatry (1992) [Pubmed]
  22. Developing a screening index for community studies of somatization disorder. Swartz, M., Hughes, D., George, L., Blazer, D., Landerman, R., Bucholz, K. Journal of psychiatric research. (1986) [Pubmed]
  23. Screening of somatization disorder: validation of the Spanish version of the Othmer and DeSouza test. García-Campayo, J.J., Sanz-Carrillo, C., Perez-Echeverria, M.J., Campos, R., Lobo, A. Acta psychiatrica Scandinavica. (1996) [Pubmed]
  24. Alterations of benzodiazepine receptor binding potential in anxiety and somatoform disorders measured by 123I-iomazenil SPECT. Tokunaga, M., Ida, I., Higuchi, T., Mikuni, M. Radiation medicine. (1997) [Pubmed]
WikiGenes - Universities